Interaction between smoking and the stromelysin-1 (MMP3) gene 5A/6A promoter polymorphism and risk of coronary heart disease in healthy men

Annals of Human Genetics

Volumn 66, Issue 5-6, 2002, Pages 343-352

  Humphries, S E ^a   Martin, S ^a   Cooper, J ^b   Miller, G ^b   Humphries, Steve ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DNA; STROMELYSIN;

ACUTE HEART INFARCTION; ADULT; AGE DISTRIBUTION; ALLELE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY SURGERY; DNA DETERMINATION; ELECTROCARDIOGRAM; FATALITY; FOLLOW UP; GENE INTERACTION; GENERAL PRACTICE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HEALTH BEHAVIOR; HEART DEATH; HETERODUPLEX ANALYSIS; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; LOGISTIC REGRESSION ANALYSIS; MALE; NORMAL HUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; Q WAVE; QUESTIONNAIRE; REVIEW; SMOKING; SMOKING HABIT; UNITED KINGDOM; UNSTABLE ANGINA PECTORIS;

ALLELES; ANGINA, UNSTABLE; CHOLESTEROL; CORONARY DISEASE; FOLLOW-UP STUDIES; GENE FREQUENCY; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); PROSPECTIVE STUDIES; RISK; RISK FACTORS; SMOKING; TRIGLYCERIDES;

ANGINA;

EID: 0036867445     PISSN: 00034800     EISSN: 14691809     Source Type: Journal    
DOI: 10.1017/S0003480002001264     Document Type: Article

References (50)

1. Abbott, R. D., Wilson, P. W. et al. (1988). High-density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study. Arteriosclerosis 8, 207–211.
2. Allen, D. R., Browse, N. L. et al. (1988). The effect of cigarette smoke, nicotine, and carbon monoxide on the permeability of the arterial wall. J. Vasc. Surg. 7, 139–152.
3. Bergmann, S., Siekmeier, R. et al. (1998). Even moderate cigarette smoking influences the pattern of circulating monocytes and the concentration of sICAM-1. Respir. Physiol. 114, 269–275.
4. Blann, A. D. (1992). The acute influence of smoking on the endothelium. Atherosclerosis 96, 249–250.
5. Bolla, M. K., Martin, S. G. et al. (2000). Genotyping of the stromelysin-1 5A/6A promoter polymorphism using a heteroduplex generator. Thromb. Haemost. 83, 790–792.
6. Bostom, A. G., Cupples, L. A. et al. (1996). Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA 276, 544–548.
7. Buttice, G., Quinones, S. et al. (1991). The AP-1 site is required for basal expression but is not necessary for TPA-response of the human stromelysin gene. Nucleic Acids Res. 19, 3723–3731.
8. Carty, C. S., Soloway, P. D. et al. (1996). Nicotine and cotinine stimulate secretion of basic fibroblast growth factor and affect expression of matrix metalloproteinases in cultured human smooth muscle cells. J. Vasc. Surg. 24, 927–934.
9. Castelli, W. P., Garrison, R. J. et al. (1986). Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256, 2835–2838.
10. Dalmon, J., Laurent, M. et al. (1993). The human beta fibrinogen promoter contains a hepatocyte nuclear factor 1-dependent interleukin-6-responsive element. Mol. Cell. Biol. 13, 1183–1193.
11. de Maat, M. P., Jukema, J. W. et al. (1999). Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am. J. Cardiol. 83, 852–856.
12. Diaz Meco, M. T., Quinones, S. et al. (1991). Protein kinase C-independent expression of stromelysin by platelet-derived growth factor, ras oncogene, and phos-phatidyl-choline-hydrolyzing phospholipase C. J. Biol. Chem. 266, 22597–22602.
13. Doll, R. & Hill, A. B. (1966). Mortality of British doctors in relation to smoking; observation on coronary thrombosis. Natl. Cancer Inst. Monogr. 19, 205–268.
14. Eliasson, B., Mero, N. et al. (1997). The insulin resistance syndrome and postprandial lipid intolerance in smokers. Atherosclerosis 129, 79–88.
15. Feo, S., Antona, V. et al. (2001). Conserved structure and promoter sequence similarity in the mouse and human genes encoding the zinc finger factor BERF-1/ BFCOL1/ZBP-89. Biochem. Biophys. Res. Commun. 283, 209–218.
16. Fickl, H., Van Antwerpen, V. L. et al. (1996). Increased levels of autoantibodies to cardiolipin and oxidised low density lipoprotein are inversely associated with plasma vitamin C status in cigarette smokers. Atherosclerosis 124, 75–81.
17. Frosst, P., Blom, H. J. et al. (1996). A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 94, 2410–2416.
18. Henney, A. M., Wakeley, P. R. et al. (1991). Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc. Natl. Acad. Sci. U.S.A. 88, 8154–8158.
19. Hokanson, J. E. & Austin, M. A. (1996). Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J. Cardiovasc. Risk 3, 213–219.
20. Humphries, S. E., Luong, L. A. et al. (1998). The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lopid Coronary Angiography Trial. Atherosclerosis 139, 49–56.
21. Humphries, S. E., Talmud, P. J. et al. (2001). Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet 358, 115–119.
22. Imai, K., Yokohama, Y. et al. (1995). Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. Activation of the precursor, interaction with other matrix metalloproteinases and enzymic properties. J. Biol. Chem. 270, 6691–6697.
23. Inoue, I., Goto, S. et al. (2000). Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci. 67, 863–876.
24. Jensen, E. J., Pedersen, B. et al. (1998). Blood eosinophil and monocyte counts are related to smoking and lung function. Respir. Med. 92, 63–69.
25. Li, R., Boerwinkle, E. et al. (2000). Glutathione S-transferase genotype as a susceptibility factor in smoking-related coronary heart disease. Atherosclerosis 149, 451–462.
26. Lowe, G. D. (1993). Blood viscosity and cardiovascular risk. Curr. Opin. Lipidol. 4, 283–287.
27. Ma, J., Stampfer, M. J. et al. (1996). Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 94, 2410–2416.
28. Mach, F., Schonbeck, U. et al. (1997). Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 96, 396–399.
29. Meade, T. W., Mellows, S. et al. (1986). Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 2, 533–537.
30. Medical Research Council's Committee on Research into Chronic Bronchitis, Questionnaire on respiratory symptoms. (1995).
31. Miller, G. J., Bauer, K. A. et al. (1995). The effects of quality and timing of venepuncture on markers of blood coagulation in healthy middle-aged men. Thromb. Haemost. 73, 82–86.
32. Miller, G. J., Bauer, K. A. et al. (1996). Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease. Thromb. Haemost. 75, 767–771.
33. Miller, S. A. & Dykes, D. D. et al. (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16, 1215.
34. Newby, A. C., Southgate, K. M. et al. (1994). Extracellular matrix degrading metalloproteinases in the pathogenesis of arteriosclerosis. Basic Res. Cardiol. 89, Suppl. 1, 59–70.
35. Powell, J. T. (1998). Vascular damage from smoking: disease mechanisms at the arterial wall. Vasc. Med. 3, 21–28.
36. Prineas, R. J., Crow, R. S. et al. (1982). The Minnesota Code Manual of Electrocardiographic Findings: standards and procedures for measurement and classification.
37. Quinones, S., Buttice, G. et al. (1994). Promoter elements in the transcriptional activation of the human stromelysin-1 gene by the inflammatory cytokine, interleukin 1. Biochem. J. 302, 471–477.
38. Schonbeck, U., Mach, F. et al. (1997). Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture ? Circ. Res. 81, 448–454.
39. Schonbeck, U., Mach, F. et al. (1999). Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo. J. Exp. Med. 189, 843–853.
40. Seed, M., Humphries, S. E. et al. (2001). Lipoprotein (a) as a predictor for myocardial infarction in the Second Northwick Park Heart Study - a prospective study in middle-aged men. Am. J. Med. Assoc. 200, 22–27.
41. Silence, J., Lupu, F. et al. (2001). Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler. Thromb. Vasc. Biol. 21, 1440–1445.
42. Shapiro, S. D., Fliszar, C. J. et al. (1995). Activation of the 92-kDa gelatinase by stromelysin and 4-amino-phenylmercuric acetate. Differential processing and stabilization of the carboxyl-terminal domain by tissue inhibitor of metalloproteinases (TIMP). J.Biol. Chem. 270, 6351–6356.
43. Talmud, P. J., Bujac, S. et al. (2000). Substitution of asparagine for aspartic acid at residue 9 (D9N) of lipoprotein lipase markedly augments risk of coronary heart disease in male smokers. Atherosclerosis 149, 75–81.
44. Terashima, M., Hozuka, A. et al. (1999). Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation 99, 17–19.
45. Wilson, P. W., Abbott, R. D. et al. (1996). High density lipoprotein cholesterol and mortality. Arteriosclerosis 276, 544–548.
46. World Health Organization Regional Office for Europe, Myocardial infarction Community register (1976). Public Health Eur. 5, 157–164.
47. Ye, S., Eriksson, P. et al. (1996). Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J. Biol. Chem. 271, 13055–13060.
48. Ye, S., Humphries, S. et al. (1998). Matrix metalloproteinases: implication in vascular matrix remodelling during atherogenesis. Clin. Sci. 94, 103–110.
49. Ye, S., Watts, G. F. et al. (1995). Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br. Heart J. 73, 209–215.
50. Ye, S., Whatling, C. et al. (1999). Human stromelysin gene promoter activity is modulated by transcription factor ZBP-89. FEBS Lett. 450, 268–272.